Evidence map›Paper›PMID 31614564›Full record

ArticleJournal of clinical medicine2019

Nicoletta Urbano, Manuel Scimeca, Antonio Crocco, Alessandro Mauriello, Elena Bonanno, Orazio Schillaci

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer.International journal of molecular sciences · 2023
    Article
  6. Insights into the Relationship between Pentraxin-3 and Cancer.International journal of molecular sciences · 2022
    Review
  7. [Molecular and cellular biochemistry · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nicoletta UrbanoNuclear Medicine, Policlinico "Tor Vergata", 00133 Rome, Italy. n.urbano@virgilio.it.
Manuel ScimecaDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy. manuel.scimeca@uniroma2.it.ORCID 0000-0003-0585-1309
Antonio CroccoDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy. crocco.antonio@hotmail.it.
Alessandro MaurielloDepartment of Experimental Medicine, University "Tor Vergata", 00133 Rome, Italy. alessandro.mauriello@uniroma2.it.
Elena BonannoDepartment of Experimental Medicine, University "Tor Vergata", 00133 Rome, Italy. elena.bonanno@uniroma2.it.
Orazio SchillaciDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy. orazio.schillaci@uniroma2.it.
University of Rome Tor Vergata · ITPoliclinico Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main aim of this study was to investigate the possible association between

Indexed as

18F–cholinebone biomarkersnuclear medicinepositron emission tomographyprostate cancer

Identifiers

PMID31614564
PMCPMC6832450
OpenAlexW2979962946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.